Inicio・Lista de Acciones・Omeros Corp

Omeros Corp

Cerrado

SectorSanidad

13.2 0.69

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

12.99

Máximo

13.29

Métricas clave
By Trading Economics
Ingresos	-35M 51M
Ventas	9.9M 9.9M
P/B Media del Sector	11.018 68.51
BPA	0.57
Margen de beneficios	518.033
Empleados	175
EBITDA	86M 57M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+149.06% upside

Dividendos
By Acuity
Próximas Ganancias	13 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-127M 909M
Apertura anterior	12.51
Cierre anterior	13.2

Noticias sobre sentimiento de mercado

By Acuity

14%

86%

12 / 340 Clasificación en Healthcare

Omeros Corp Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

8 ago 2026, 00:02 UTC

Omeros Corp shares are lower in after-market hours, showing notable volatility since Friday's close. The stock remains above its 20-day moving average.

7 ago 2026, 23:31 UTC

Omeros Corp shares are trading lower in after-market hours, despite strong performance in the broader market, particularly among major tech stocks.

6 ago 2026, 23:01 UTC

Omeros Corp shares are lower in after-market hours, with no specific news identified. Recent economic data may influence expectations of Federal Reserve tightening.

5 ago 2026, 23:51 UTC

Omeros Corp shares are higher in after-market trading. Broader market sentiment is influenced by disappointing ADP employment data as investors await Non-Farm Payrolls.

4 ago 2026, 23:02 UTC

Omeros Corp shares are lower in after-hours trading, reversing an initial gain despite strong recent performance above its 20-day moving average.

3 ago 2026, 23:11 UTC

Event

Omeros Corp shares are lower in after-market trading following the CMS announcement on YARTEMLEA. The stock remains above its 20-day moving average.

1 ago 2026, 00:01 UTC

Omeros Corp shares are higher in after-market trading, reaching a notable high and staying above the 20-day moving average. No specific news was identified.

31 jul 2026, 23:41 UTC

Omeros Corp shares are higher in after-market trading, significantly above their 20-day moving average and near the upper end of their one-month range.

30 jul 2026, 16:06 UTC

Omeros Corp shares are higher today, continuing a steady increase since Wednesday. The stock trades near the upper end of its one-month range.

29 jul 2026, 18:58 UTC

Social Media

Omeros Corp is trading higher today, driven by positive social media sentiment despite broader weakness in the XBI sector. Market volume remains unusually high.

28 jul 2026, 19:16 UTC

Social Media

Omeros Corp shares are lower today after earlier declines, amid social media discussions highlighting reduced competition following AstraZeneca's failed trial related to HSCT-TMA.

27 jul 2026, 21:01 UTC

Omeros Corp shares are higher in after-market hours, following a broader market trend amid easing geopolitical tensions and declining oil prices.

24 jul 2026, 19:26 UTC

Omeros Corp shares are lower today, continuing a decline since Thursday's close, with no specific news identified to explain the movement.

22 jul 2026, 18:46 UTC

Omeros Corp shares are higher today, continuing an upward trend since Tuesday. Broader market dynamics are influenced by rising crude oil prices amid geopolitical tensions.

21 jul 2026, 23:06 UTC

Omeros Corp. shares traded roughly flat in after-market hours. The stock remains below its 20-day moving average, marking three consecutive lower daily closes.

20 jul 2026, 19:26 UTC

Omeros Corp shares are higher today, despite an earlier pullback. The stock has stabilized since Friday's close within its one-month trading range.

Comparación entre iguales

Cambio de precio

Omeros Corp previsión

Precio Objetivo

By TipRanks

149.06% repunte

Estimación a 12 Meses

Media 33 USD 149.06%

Máximo 33 USD

Mínimo 33 USD

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Omeros Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

2 ratings

Comprar

Mantener

Vender

De acuerdo con 2 analistas que ofrecen calificaciones bursátiles a para Omeros Corp Dist en los últimos 3 meses.

Sentimiento

By Acuity

12 / 340 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Omeros Corp

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.